To be competitive, maximize products and deliver exceptional customer service, trade and channel strategies must go beyond logistics. This presentation outlines how manufacturers need to connect the dots between customer type, whether they are specialty distributors,…
The traditional mindset toward established brands in the pharmaceutical industry has largely been to let focus fade from them and shift entirely to developing and launching new products. With emphasis placed almost exclusively on new product…
Maximizing revenue potential throughout products’ entire lifecycles before they reach loss of exclusivity (LOE) is the most impactful return on investment manufacturers can make for their established brands. While many companies figuratively put their mature brands…
Product launch preparedness is a vital aspect of bringing new products to market, particularly in the pharmaceutical industry where patients’ health and well-being can be impacted, in addition to the brand’s success and overall reputation. As…
The pharmaceutical industry faces a host of increasingly complex challenges and critical decisions when attempting to manage and predict their products’ plausible revenue patterns. The mishandling of revenue forecasting and evaluation can result in substantial financial…
EVERSANA’s Chris Lagoerio, Vice President, Revenue Management participated in a panel session, “Innovative Approaches to 340B Claims Data Identification,” at the Medicaid & Government Pricing Congress alongside fellow industry leaders Andrew Brownlee, Associate Director, Berkeley Research…
Pharmaceutical manufacturers commonly invest a considerable amount of time, money and additional resources into revenue management. Most would likely say they desire to invest even more because of the significant impact it has on their products’…
Pharmaceutical manufacturers specializing in Rare Disease, Oncology, Personalized Cancer Immunotherapy, and Cell and Gene therapies encounter a range of complex challenges, including advancements in medicine and technology, changing patient and provider needs, market access, regulatory pathways,…
Strategically pricing new therapies has always been vitally important for pharmaceutical manufacturers. After the 2022 passing of the historic legislative package, known as the Inflation Reduction Act (IRA), strategic pricing strategies have become especially pivotal. The…
2023 is shaping up to be an interesting year for Pharma/Biotech companies and their commercial and government pricing strategies and contracts. There are multiple policies and rules being discussed, already proposed, under review, in litigation, and…